Literature DB >> 23343175

Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.

Aziz Nazha1, Zeev Estrov, Jorge Cortes, Carlos E Bueso-Ramos, Hagop Kantarjian, Srdan Verstovsek.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23343175      PMCID： PMC4135587          DOI： 10.3109/10428194.2013.769537

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2010-10-14       Impact factor: 22.113

Review 2.  Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Authors:  Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence A Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Hagop Kantarjian; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Journal:  Leuk Res       Date:  2007-01-08       Impact factor: 3.156

3.  Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.

Authors:  J Thiele; H M Kvasnicka
Journal:  Ann Hematol       Date:  2006-01-19       Impact factor: 3.673

4.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

5.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

7.  Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.

Authors:  Claudia Vener; Nicola Stefano Fracchiolla; Umberto Gianelli; Rossella Calori; Franca Radaelli; Alessandra Iurlo; Sabrina Caberlon; Giancarla Gerli; Leonardo Boiocchi; Giorgio Lambertenghi Deliliers
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

8.  Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Gianluca Viarengo; Laura Villani; Umberto Magrini
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240
  8 in total
  7 in total

Review 1.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

Review 2.  Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors:  Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

Review 3.  Survival analysis, more than meets the eye.

Authors:  Marko Lucijanic; Marko Skelin; Tomo Lucijanic
Journal:  Biochem Med (Zagreb)       Date:  2017-02-15       Impact factor: 2.313

4.  Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34+ cells.

Authors:  Giulia Pozzi; Cecilia Carubbi; Giuliana Gobbi; Sara Tagliaferri; Prisco Mirandola; Marco Vitale; Elena Masselli
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

5.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Massimiliano Bonifacio; Mario Tiribelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mariella D'Adda; Nicola Polverelli; Micaela Bergamaschi; Alessia Tieghi; Francesco Cavazzini; Adalberto Ibatici; Monica Crugnola; Costanza Bosi; Roberto Latagliata; Ambra Di Veroli; Luigi Scaffidi; Federico de Marchi; Elisa Cerqui; Barbara Anaclerico; Giovanna De Matteis; Marco Spinsanti; Elena Sabattini; Lucia Catani; Franco Aversa; Francesco Di Raimondo; Umberto Vitolo; Roberto Massimo Lemoli; Renato Fanin; Francesco Merli; Domenico Russo; Antonio Cuneo; Maria Letizia Bacchi Reggiani; Michele Cavo; Nicola Vianelli; Massimo Breccia
Journal:  Oncotarget       Date:  2017-06-27

Review 6.  Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.

Authors:  Xue Bin Wu; Wei Wei Wu; Yue Zhou; Xuan Wang; Jia Li; Yang Yu
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

7.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.